Home Blog Page 1935

Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session

By
Advertorial Desk
-

SUZHOU, China, Oct. 18, 2025 /PRNewswire/ — Alphamab Oncology (Stock Code: 9966.HK) announced that the first interim analysis results of a phase III clinical trial of anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (stock code: 1093.HK), in combination with chemotherapy as second-line or above treatment of HER2-positive gastric cancer (GC) (including gastroesophageal junction cancer (GEJ)) (Study ID: KN026-001, also known as KC-WISE), have been presented at the 2025 European Society for Medical Oncology Congress (ESMO Congress 2025) Late-Breaking Abstract (LBA) Oral Presentation Session.

LBA Oral Presentation Session is a highly anticipated global highlight of the ESMO Congress. The research presented in this category is both highly topical and of significant clinical value. Their findings often herald potential impacts on current clinical practice and can even guide the future direction of entire therapeutic fields.

Title：KN026 in combination with chemotherapy for previously treated HER2-positive gastric or gastroesophageal carcinomas (GC/GEJC): Interim analysis of KC-WISE
Number: LBA 78
Speaker: Jianming Xu, Chinese PLA General Hospital
Date：Friday, 17 October 2025

METHODS

Enrolled patients in study KN026-001 (KC-WISE) with HER2-positive GC/GEJ who had disease progression after trastuzumab-based therapy were randomized to receive either anbenitamab (KN026) in combination with chemotherapy (the “Anbenitamab Group”) or chemotherapy with placebo (the “Control Group”). The patients were stratified based on (i) type of chemotherapy, (ii) HER2 expression level, and (iii) number of prior lines of treatments.

RESULTS

At baseline, patient characteristics were generally well balanced between the two groups. The median age was approximately 64 in the Anbenitamab Group and 61 in the Control Group. In both groups, over 80% of patients had an ECOG PS of 1, and nearly all patients were diagnosed with stage IVB disease at enrollment. All patients had previously received chemotherapy, most commonly taxanes (over 70%), with the remainder receiving irinotecan-based regimens.

As of April 3, 2025, the median follow-up duration was 9.7 months (95% CI, 7.2 to 11.9 months) in the Anbenitamab Group and 9.8 months (95% CI, 7.4 to 12.9 months) in the Control Group.

Efficacy as assessed by the Independent Review Committee (IRC):

  • The median treatment-related adverse event (PFS) for the Anbenitamab Group was 7.1 months, compared with 2.7 months in the Control Group. The hazard ratio (HR) is 0.25 (P value is 5.44 × 10⁻¹²), corresponding to a 75% reduction in the risk of disease progression or death.
  • The median overall survival (OS) for the Anbenitamab Group was 19.6 months (not mature), compared with 11.5 months in the Control Group. The HR is 0.29, representing a 71% reduction in the risk of death, and P value is 1.56 × 10⁻6, which is well below the prespecified extremely stringent alpha threshold of 0.00001.
  • The objective response rate (ORR) was 55.8% in the Anbenitamab Group versus 10.8% in the Control Group, while the disease control rate (DCR) was 80.0% and 41.9%, respectively. The median duration of response (DoR) was 8.2 months and 2.9 months, respectively.

Safety:

  • The median treatment duration was 6.5 cycles in the Anbenitamab Group and 3.0 cycles in the Control Group.
  • The incidence of Grade 3 treatment-emergent adverse events (TEAEs) or above was 60.6% in the Anbenitamab Group and 51.6% in the Control Group, while the incidence of serious adverse events (SAEs) was 31.9% and 33.3%, respectively.
  • The most frequently observed Grade 3 treatment-related adverse events (TRAEs) or above in the Anbenitamab Group included neutropenia (29.8%), leukopenia (21.3%), anemia (18.1%), diarrhea (8.5%) and asthenia (8.5%), while the most frequently observed Grade 3 TRAEs or above in the Control Group included leukopenia (24.7%), neutropenia (21.5%), anemia (10.8%), diarrhea (7.5%) and thrombocytopenia (5.4%). The incidence of cardiotoxicity in both groups were both 3.2%, indicating fewer cardiac concerns.

CONCLUSIONS

The interim analysis demonstrated that anbenitamab achieved superior efficacy in second-line or third-line HER2-positive gastric cancer patients who had been previously treated with trastuzumab. The study met both its primary endpoints of PFS and OS with statistically significant and clinically meaningful improvements, indicating its potential to change clinical practice guidelines for the treatment of second-line or above gastric cancer. Compared with the recently published DESTINY-Gastric04 results of DS-8201 in second-line gastric cancer, anbenitamab demonstrates potential advantages in both efficacy and safety.

Prompted by these encouraging results of anbenitamab, we are preparing to expand clinical development into first-line and perioperative gastric cancer through new registrational trials, aiming to extend benefits to more patients. Meanwhile, JSKN003, an ADC built upon KN026, has demonstrated high-security profile and distinctive advantages. With multiple registrational studies currently advancing as planned, we anticipate even more outstanding performance from JSKN003 in the future.

About Anbenitamab (KN026)

Anbenitamab (KN026) is an anti-HER2 bispecific antibody independently developed by Alphamab Oncology using the proprietary Fc-based heterodimer bispecific platform technology called CRIB (Charge Repulsion Induced Bispecific). KN026 can simultaneously bind two non-overlapping epitopes of HER2, resulting in HER2 signal blockade.

Results from multiple clinical studies showed that KN026 has promising efficacy for the treatment of HER2-positive solid tumors, both in the first-line and in patients previously treated with trastuzumab. Currently, several pivotal trials of KN026 for second-line or above HER2-positive GC/gastroesophageal junction cancer (GEJ), first-line HER2-positive BC, neoadjuvant treatment of HER2-positive BC are being conducted. KN026 for the treatment of patients with HER2-positive GC  who have failed first-line standard treatment was granted breakthrough therapy designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China (NMPA). KN026 for the treatment of HER2-positive or low expressing GC was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). In September 2025, the first New Drug Application (NDA) for anbenitamab injection has been accepted by the NMPA for use in combination with chemotherapy in patients with HER2-positive locally advanced, recurrent, or metastatic GC/GEJ who have failed at least one prior systemic therapy (which must include trastuzumab in combination with chemotherapy).

In August 2021, the Company entered an agreement with JMT-Bio Technology Co., Ltd. (“JMT-Bio”), a wholly-owned subsidiary of CSPC Pharmaceutical Group Co., Ltd. (“CSPC”) (stock code: 1093.HK), for the development and commercialization of KN026 in Mainland China. JMT-Bio was granted exclusive license rights of KN026 for the development and commercialization in the indications of BC an GC/GEJ in Mainland China (excluding Hong Kong, Macau and Taiwan).

About Alphamab Oncology

Alphamab Oncology is an innovative biopharmaceutical company focused on oncology. On December 12, 2019, the Company was successfully listed on the Main Board of the Hong Kong Stock Exchange (Stock Code: 9966.HK).

Leveraging proprietary platforms-including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations-the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies.

One product has received market approval: Envafolimab (KN035, brand name: 恩维达®), the world’s first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Four bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines—such as dual-payload ADCs—are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms.

Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, delivering China-innovated cancer therapies to benefit patients worldwide.

From “Wheels” to a “Three-Dimensional Ecosystem”: The 2025 Chery Global Innovation Conference Unveils a New Blueprint for Intelligent Mobility

By
Advertorial Desk
-

WUHU, China, Oct. 18, 2025 /PRNewswire/ — A clear and composed “Hello everyone, I’m Mornine” ignited the climax of the 2025 Chery Global Innovation Conference.

This unique “presenter” was none other than AiMOGA robot Mornine.

In a ten-minute fully autonomous presentation, she reviewed AiMOGA’s journey from concept to real-world deployment across more than 30 countries and demonstrated multilingual interaction and scenario-based applications, outlining a vivid vision of “car-machine collaboration.”

AiMOGA Robot “Mornine” on stage at the Innovation Conference
AiMOGA Robot “Mornine” on stage at the Innovation Conference

Mornine’s remarkable appearance became a vivid illustration of the conference theme, “Innovation • Intelligence Leading the World.”

As one of the core activities of the 2025 Chery International User Summit, the Innovation Conference brought together academicians, top global experts, industry leaders, media, and partners to witness Chery’s breakthrough transformation toward a full-scenario intelligent ecosystem.

From Presenter to Experience Officer: A Robot‘s Ecosystem Showcase

Mornine’s highlights extended beyond the main stage.

In the outdoor demonstration area, her “multi-agent collaboration” became another focus of attention.

From professional introductions and vehicle guidance to door-opening demonstrations, every step was completed autonomously.

With the coordination of her vision-tactile dexterous hand and multi-expression interaction system, Mornine impressed visitors with fluent demonstrations—pouring water, opening car doors, and other signature actions that drew rounds of applause.

Dr. Gao Xinhua delivers a keynote presentation
Dr. Gao Xinhua delivers a keynote presentation

Dr. Gao Xinhua, CTO of Chery Group, stated during his keynote:

“Our technology evolution is expanding from ‘wheels’ to a ‘three-dimensional ecosystem,’ and intelligent robots are a natural extension of this strategy.”

This vision is reflected in AiMOGA’s technical details:

its ±5 cm precision autonomous navigation and dynamic obstacle avoidance builds on Chery’s achievements in intelligent driving;

and its 17-degree-of-freedom vision-tactile dexterous hand integrates Chery’s electromechanical and control system expertise.

The Strength of “Tech Chery”: Five Domains of Breakthrough Innovation Behind AiMOGA’s impressive performance lies the technological foundation of “Tech Chery.”

At this year’s Innovation Conference, Chery unveiled major breakthroughs across five key technology domains, releasing more than ten world-leading innovations.

The new Kunpeng engine set a new global benchmark with over 48% thermal efficiency;

the high-energy solid-state battery achieved 600 Wh/kg, near the theoretical lithium limit;

the Luoshu AI large model covers 1,000+ vehicle control functions, with response time <1000 ms and task accuracy >95%;

the Falcon 900 intelligent driving system integrates VLA and world modeling, targeting L3–L4 autonomous driving with full safety redundancy.

From leading hybrid performance to human-centered intelligent interaction, from key breakthroughs to full-ecosystem development, Chery is transforming its 28 years of technological expertise into a key to the future — opening a new era of global intelligent mobility.

From Wuhu to the World: A New Global Identity for the Future

Just before the conference, AiMOGA Robotics achieved a series of EU certifications, becoming the world’s first robot to complete both hardware and software compliance. This milestone marks a new chapter in Chery’s global ecosystem — from Poland to Malaysia, Indonesia to South Africa, AiMOGA Dedicated To Embodied Intelligence. Be Committed To Building World-Leading And Trusted AI Assistants. Behind this growing global footprint lies AiMOGA’s powerful R&D network — spanning Shanghai, Europe, and North America, and collaborating with top universities.

This multidimensional R&D ecosystem fuels AiMOGA’s ongoing evolution and serves as a strong foundation for Chery’s global innovation strategy.

AiMOGA Robot interactive experience zone outside the venue
AiMOGA Robot interactive experience zone outside the venue

From AiMOGA Robotics leading the era of embodied intelligence to Chery’s progress across five technological frontiers, a new vision of intelligent mobility is emerging.

Within this ecosystem, robots have become the natural bridge between people, vehicles, and services.

From showrooms to city blocks, from production lines to living spaces, Chery is building a future where humans and robots coexist harmoniously and technology integrates seamlessly with real-world scenarios.

At this moment, on the stage of the 2025 Chery Global Innovation Conference, we are witnessing not just a product release, but the beginning of a new era.

Looking ahead, Chery will continue to drive innovation and speak the language of intelligence, joining global partners to usher in a new era of human-robot symbiosis and intelligent connectivity.

SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025

By
Advertorial Desk
-

SINGAPORE, Oct. 18, 2025 /PRNewswire/ — SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing next-generation immunotherapies for infectious diseases and their associated cancers, announced the presentation of first-in-human clinical data for SCG142 in an investigator-initiated Phase I trial (NCT06544720) in patients with recurrent or metastatic HPV-associated carcinomas. The poster will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany, on Saturday, 18 October 2025.

This ongoing first-in-human trial evaluates the safety, tolerability and preliminary efficacy of SCG142, a novel human papillomavirus (HPV) E7-specific T-cell receptor-engineered T (TCR T) cell therapy armoured with a TGFβRII-41BB chimeric switch receptor. Eligible patients are HLA-A*02:01-positive with advanced HPV16- or HPV52-positive carcinomas who have progressed on or were intolerant to at least one prior systemic therapy. Key endpoints include safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity. As of the data cut-off, tumor shrinkage was observed in all seven treated patients, resulting in a disease control rate (DCR) of 100%. Four of the seven patients (57%) achieved >30% tumor reduction, including two confirmed partial responses (PR) and two unconfirmed PRs. No dose-limiting toxicities or serious adverse events were reported. These preliminary findings support continued clinical development of SCG142.

“SCG142 is a novel and differentiated HPV-specific TCR T cell therapy with promising clinical activity.” said Prof. Dr. Yang Li, Director of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University. “We’re excited that tumor shrinkage was observed in all seven treated patients and that SCG142 was well tolerated. These encouraging preliminary findings underscore the potential of SCG142 to provide new solutions for patients in a variety of HPV16 and HPV52 expressing cancers and support further evaluation in larger patient cohorts”, she added.

SCG142 was isolated with GianTCRTM, SCG’s proprietary TCR screening platform with the ability to identify fully natural TCRs with high affinity and high avidity properties as well as potent antiviral and anti-tumor effects against infection-related solid tumors accompanied by a lower risk of off-target toxicity. “We are delighted that the excellent preclinical profile of our HPV-E7-specific TCR – including high avidity and dual functionality in both CD8+ and CD4+ T cells – has translated into clinical activity with SCG142″ added Dr. Susanne Wilde, VP, Head of Preclinical Research of SCG Cell Therapy.

Besides SCG142, SCG is also advancing SCG101, a hepatitis B virus (HBV)-specific TCR T cell therapy for the treatment of HBV-related hepatocellular carcinoma (HCC).

– END –

About Human Papillomavirus and Cancers

Human papillomavirus (HPV) infection is the most common sexually transmitted infection. Nearly all sexually active people are infected with HPV and around half of these infections occur with a high-risk HPV type, which can lead to cancer development.1 As such, HPV infection accounts for more than 90% of anal and cervical cancers, about 70% of vaginal and vulvar cancers, and 60% of penile and oropharyngeal cancers, and it causes an estimated 690,000 cancers worldwide each year[1],[2].

About SCG Cell Therapy

SCG is a leading biotechnology company focusing on the development of novel immunotherapies in infections and its associated cancers. The company targets the most common cancer-causing infections:  HPV, HBV and EBV, and develops a broad and unique pipeline of TCR-based cellular immunotherapy products against infection- associated cancers. With the proprietary GianTCRTM TCR screening platform, in house viral vector production and AutoCellTM, a fully closed, automatic and low-cost cell therapy manufacturing system, the company covers the entire value chain from new target research and discovery, manufacturing, and clinical development. For more information about SCG, please visit us at www.scgcell.com.

[1] HPV and cancer. National Cancer Institute. (2025, May 9)

[2] Basic information about HPV and cancer. Centers for Disease Control and Prevent (2024, September 17）

 

 

Joyful Alliance Proposes Sustainable Integrated Onsen Resort to Japan’s Wakayama City, Targeting the World’s First Zero-Carbon Destination with USD 2.2 B Investment

By
Advertorial Desk
-

HONG KONG SAR – Media OutReach Newswire – 18 October 2025 – Joyful Alliance, a Singapore-headquartered investment firm, today announced it will propose the development of the Wakayama Integrated Onsen Resort to the Wakayama City Government. The two parties officially signed the memorandum of cooperation on October 17.

Joyful Alliance will propose an Integrated Onsen Resort development in Wakayama City, Japan, projected to attract millions of visitors annually. (From right to left) Mr. Simon Chua, Executive Counsel for the Wakayama City Urban Regeneration Corporation; Mr. Thomas Tin, Managing Director of Joyful Alliance; Ms. Sherleen Tay, General Manager of Green Matter Hub; and Mr. Ryan Lau, Representative of CMA Testing.
Joyful Alliance will propose an Integrated Onsen Resort development in Wakayama City, Japan, projected to attract millions of visitors annually. (From right to left) Mr. Simon Chua, Executive Counsel for the Wakayama City Urban Regeneration Corporation; Mr. Thomas Tin, Managing Director of Joyful Alliance; Ms. Sherleen Tay, General Manager of Green Matter Hub; and Mr. Ryan Lau, Representative of CMA Testing.

Joyful Alliance is actively discussing a future investment in Wakayama City of over US$2.2 billion, aiming to leverage Wakayama City’s rich natural hot springs and cultural heritage to create the World’s first zero-carbon resort. Upon completion, the resort is expected to draw millions of visitors annually, injecting new vitality into Wakayama City’s tourism sector.

Wakayama City lies in Japan’s Kansai region, adjacent to Osaka. It is well connected: the site is a 30-minute drive from Kansai International Airport. The proposed Wakayama Integrated Onsen Resort is planned to be a green, zero-carbon smart resort that combines Wakayama’s millennia-old Onsen culture with entertainment facilities.

Joyful Alliance, backed by family offices from Hong Kong and Singapore, specialises in green investments, asset management and sustainable infrastructure projects. For the Wakayama Integrated Onsen Resort development proposal, Joyful Alliance has assembled an international team of partners: Green Matter Hub, a green technology platform, will supply low-carbon construction materials and intelligent energy solutions; and CMA Testing will oversee quality assurance, ensuring that every aspect of the project meets global sustainability standards.

Mr. Simon Chua, Executive Counsel for the Wakayama City Urban Regeneration Corporation, stated: “Wakayama City is a historic gem blessed with natural beauty, rich culture, and a strategic location. I am very pleased to invite Joyful Alliance to discuss this potential transformative investment.”

Mr. Thomas Tin, Managing Director of Joyful Alliance, emphasised: “We are honoured to be invited to discuss this historic project. We believe this project will generate tens of thousands of jobs in surrounding areas and lead the industry with green zero-carbon technologies. Given our background in green technology, we hope to bring outstanding green tech innovations from Hong Kong to collaborate locally when building in Japan. We will leverage our expertise in green investment and sustainable development to work with the team to propose a resort imbued with Wakayama City’s local character.”

Ms. Sherleen Tay, General Manager of Green Matter Hub, noted: “We are thrilled to support the upcoming Wakayama project in achieving carbon neutrality. Through our digital ecosystem, including combining certification, carbon tracking, and fintech services, we’re shaping a low-carbon future.”

Mr. Ryan Lau, representative of CMA Testing, added: “As a greenhouse verification body, we will provide expert guidance to ensure that every step of this project aligns with international standards while honouring Japan’s local regulations and environmental goals.”

Hashtag: #JoyfulAlliance

The issuer is solely responsible for the content of this announcement.

Joyful Alliance

Joyful Alliance is a forward-looking investment company based in Singapore, backed by a consortium of family offices from both Hong Kong and Singapore. We are committed to delivering long-term value to our clients through strategic asset management, innovative financial solutions, and disciplined investment practices.

Our services are grounded in the principles of integrity and performance, catering to a diverse clientele ranging from individual investors to institutional partners. For more information, visit .

AiMOGA Robotics Becomes the Centerpiece of Co-Creation at the 2025 Chery International User Summit

By
Advertorial Desk
-

WUHU, China, Oct. 18, 2025 /PRNewswire/ — Under the theme “Co-Create • Co-Define,” the 2025 Chery International User Summit opened with great momentum in Wuhu, China.

As Chery’s annual flagship event for global users, the summit showcased the group’s latest progress in new energy and intelligent mobility, while unveiling forward-looking achievements across its smart ecosystem.

Among all highlights, AiMOGA Robotics, the intelligent robotics division of Chery Group, drew widespread attention as the most symbolic presence of embodied intelligence under the identity of “your trusted human AI assistant.”

2025 Chery International User Summit
2025 Chery International User Summit

From Scene to Ecosystem: Human-Robot Collaboration in Action

As a key member of Chery’s intelligent ecosystem, AiMOGA robots appeared across multiple brand zones — including CHERY, EXEED, OMODA & JAECOO, iCAUR, LEPAS, and LUXEED — taking on roles in product explanation, performance, and interaction.

Mornine with Users
Mornine with Users

At the CHERY pavilion, Mornine provided multilingual vehicle presentations for global visitors; in OMODA & JAECOO, she explained the Super Hybrid System (SHS) powered by the Chery large model, offering smooth and natural interaction.

During the iCAUR opening performance, Mornine and the quadruped robot Argos performed a synchronized “human-robot dance,” captivating the audience.

Technology at the Core: Advancing Embodied Intelligence

After three years of R&D, AiMOGA Robotics has achieved a technological leap from L2 (collaborative-level) to L3 (assistance-level) capability. As a key stage toward higher-level intelligence, the L3 capability not only enhances service efficiency but also enables continuous optimization of task performance, truly realizing intelligent embodiment across diverse application scenarios. This provides strong technical support for Mornine’s deployment in complex 4S dealership environments.

Meanwhile, in the Argos Challenge, the robotic dog completed complex terrain navigation and recognition tasks, highlighting strong adaptability for future security inspection and hazardous operations.

AiMOGA Robotic Dog
AiMOGA Robotic Dog

Co-Create • Co-Define: From Concept to Real Practice

The 2025 Chery International User Summit represents more than a technology showcase—it is a live demonstration of co-creation between humans and robots.

By integrating robots into real-world service roles, Chery is redefining the boundaries between mobility, intelligence, and experience.

Through its embodied collaboration across multiple brand zones, AiMOGA Robotics vividly illustrated the spirit of “Co-Create • Co-Define.”

Looking ahead, AiMOGA will continue expanding real-world applications across sales, public services, and home companionship, supporting Chery’s vision of building a holistic “Automotive + Robotics” intelligent ecosystem.

Asia Smart Innovation Awards 2025 Winners Announced Hong Kong Takes Silver and Bronze in Lifestyle and Culture Category Thailand Wins Inaugural Grand Award

By
Advertorial Desk
-

HONG KONG, Oct. 18, 2025 /PRNewswire/ — The Hong Kong Wireless Technology Industry Association (WTIA) held the Asia Smart Innovation Awards 2025 Presentation Ceremony at Cordis Hong Kong on 16 October 2025. Organized by WTIA and sponsored by the Cultural and Creative Industries Development Agency (CCIDA), the Awards are co-organized with partners from 17 other Asian countries and regions. The Awards aim to recognize outstanding achievements in smart technology and innovative applications across Asia, provide a platform for local and overseas developers to network, promote industry development, assist enterprises in business expansion, and encourage the wider adoption of smart technology and creative solutions throughout Hong Kong and Asia.

Asia Smart Innovation Awards 2025 Winners Announced
Asia Smart Innovation Awards 2025 Winners Announced

Grand Award Winner: RIFFAI from Thailand

RIFFAI from Thailand won the Asia Smart Innovation Grand Award 2025 with its project “Shorten Site Search & Selection in Energy Industry with Satellite & AI,” which also claimed the Gold Award in the Business and Commercial category. RIFFAI’s platform integrates high-resolution satellite imagery with proprietary neural networks to revolutionize site selection processes in the energy sector. By analyzing multispectral data to detect land use patterns, climate risks, and energy asset distribution with precision, the technology dramatically reduces the time and cost required for energy infrastructure planning while enabling real-time monitoring and predictive analytics.

Hong Kong Participants Secure Two Positions in Lifestyle and Culture Category

Hong Kong participants occupied two finalist positions in the Lifestyle and Culture category. The Silver Award went to 417 Technology Limited, a previous Asia Smart App Awards winner, for its project Wonderland. Wonderland transforms STEM education by turning students into active creators through game design and AI-assisted learning. The platform enables students to design their own digital experiences while developing coding, design thinking, collaboration, and creativity skills. Wonderland features AI Buddies that provide personalized guidance adapted to individual learning styles, making STEM education accessible and engaging for students from all backgrounds.

The Bronze Award winner, SMART IGNITE TECHNOLOGY LIMITED, also received the Special Mention Award for Best Startup. Its CenWatch project represents a breakthrough in the transition from mobile to wearable Internet with its innovative “light AR + heavy watch” architecture. The system combines lightweight AR glasses for immersive display with a sophisticated watch that integrates computing and connectivity functions. The core wrist-mounted LiDAR technology captures sub-millimeter finger movements in mid-air, combined with IMU and multi-modal fusion algorithms for precise gesture recognition. Users can swipe, type, and write in space without physical touch. The Gold Award in this category went to Kaz Software Ltd from Bangladesh.

Public Sector and Social Innovation Category

The Gold Award in the Public Sector and Social Innovation category was presented to bitsensing Inc from Korea for TraXight™, a next-generation Intelligent Transportation System that integrates radar, camera, and AI technologies for real-time traffic flow analysis, incident detection, and signal optimization. Evolved through the 2025 Verona K-City Network pilot program, TraXight™ can detect violations, simulate traffic policies, and optimize congestion in complex urban environments. The system transforms raw traffic data into actionable insights, enabling governments to manage mobility proactively with accurate diagnostics, real-time control, and scalable infrastructure. Other finalists competing across the three categories included smart solutions from Israel, Malaysia, and Vietnam.

Since its debut in 2013, the Asia Smart App Awards (predecessor to the current Awards) have received over 1,400 entries from across Asia and have become a highly recognized authority and annual highlight for the regional smart technology sector. This year, the Awards were officially upgraded and renamed as the “Asia Smart Innovation Awards,” expanding its scope beyond mobile applications to include IoT, Artificial Intelligence (AI), blockchain, big data, cloud computing, AR/VR, and other emerging smart technologies. This expansion reflects the diverse development of smart solutions in the region, keeps pace with global trends, and cements Hong Kong’s leadership position within Asia’s technology ecosystem. This year’s Awards continue the collaboration with organizations from Hong Kong and 17 other Asian countries and regions, including the Chinese Mainland, Taiwan, Israel, Indonesia, Japan, Korea, Malaysia, the Philippines, Singapore, Thailand, Pakistan, Vietnam, Sri Lanka, Myanmar, India, Cambodia, and Bangladesh. Representatives from these regions served as judges and participated in the Asia Smart Innovation Awards Summit.

The Award Presentation Ceremony was officiated by Dr Lawrence Cheung, Chief Technology Officer of the Hong Kong Productivity Council, and Mr. Keith Li, Chairman of the Hong Kong Wireless Technology Industry Association.

Mr. Keith Li, Chairman of WTIA, stated at the award ceremony: “In alignment with the HKSAR Government’s policy to advance innovation and technology development, we have been committed to helping our local tech industry ‘go global’ and actively fostering cross-regional collaboration and exchange. This year’s Asia Smart Innovation Awards brings together partners from 17 Asian countries and regions, exemplifying our association’s vital role as a regional technology bridge. Through this platform, Hong Kong developers compete alongside the world’s top teams, not only showcasing exceptional creativity and capabilities but also further cementing Hong Kong’s leadership as an international innovation and technology hub. With the rise of artificial intelligence, IoT, and other emerging technologies, we will continue to create more cross-regional collaboration opportunities for the industry and drive Hong Kong’s development as Asia’s smart innovation nexus.”

The Asia Smart Innovation Awards 2025 featured three award categories: Public Sector and Social Innovation, Business and Commercial, and Lifestyle and Culture. Among the nine finalists, three were from Hong Kong, with the remainder from Israel, Malaysia, Korea, Vietnam, Thailand, and Bangladesh, competing for Gold, Silver, and Bronze Awards in each category. The Grand Award winner was selected from among the Gold Award recipients across all three categories.

Additionally, this year’s awards introduced two special mention categories—the Special Mention Award for Best Startup and the Special Mention Award for Best User Experience—open to teams from Hong Kong and other participating Asian countries or regions. The “Best Startup” award was won by SMART IGNITE TECHNOLOGY LIMITED for its CenWatch, while the “Best User Experience” award went to Mocart, developed by an Israeli enterprise.

Asia Smart Innovation Awards 2025 Winners:

Grand Award
Winner: RIFFAI (Thailand)

Public Sector and Social Innovation
Gold Award: bitsensing Inc. (Korea)
Silver Award: Hong Kong Applied Science and Technology Research Institute Company Limited (Hong Kong, China)
Bronze Award: ILOTUSLAND VIET NAM JOINT STOCK COMPANY (Vietnam)

Business and Commercial
Gold Award: RIFFAI (Thailand)
Silver Award: Meraque Services Sdn Bhd (Malaysia)
Bronze Award: Mocart (Israel)

Lifestyle and Culture
Gold Award: Kaz Software Ltd (Bangladesh)
Silver Award: 417 Technology Limited (Hong Kong, China)
Bronze Award: SMART IGNITE TECHNOLOGY LIMITED (Hong Kong, China)

Special Mention Award – Best Startup
Winner: SMART IGNITE TECHNOLOGY LIMITED (Hong Kong, China)

Special Mention Award – Best User Experience
Winner: Mocart (Israel)

*Certificates of Merit were also awarded in each category. For the complete winner list, please visit https://contest2025.bestasiainnovation.hk/

The Asia Smart Innovation Awards have long been a milestone for Hong Kong’s innovation and technology sector. To date, Hong Kong participants have won over 130 awards, including Grand, Gold, Silver, Bronze, and Merit Awards, demonstrating the city’s innovative prowess. The widespread adoption of app stores and technology platforms has significantly encouraged young creative talents to join the industry, providing opportunities for the new generation of developers to innovate and compete on a global stage. The Awards aim to drive creativity in application design and development, foster cross-sector and cross-regional collaboration, and accelerate the adoption of innovative solutions. Notable success stories include Photomyne from Israel, which developed AI-powered offline photo scanning technology, and “Present AR,” an AR interactive storytelling app by Hong Kong’s 417 Technology Limited—both serving as benchmarks for innovation in Asia.

WTIA remains committed to enhancing the reach of these awards across Asia, bolstering the development of the local smart innovation industry, and facilitating local smart technology talent in business expansion. The awards have drawn participants from an increasing number of Asian countries and regions, including Hong Kong, China, Chinese mainland, Taiwan, China, Israel, Indonesia, Japan, Korea, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Sri Lanka, Myanmar, India, Cambodia, and Bangladesh, providing an excellent platform for exchange within Asia’s innovation and technology sector.

In addition to the Asia Smart Innovation Awards 2025 Presentation Ceremony held in the afternoon, the Asia Smart Innovation Summit 2025 was held on the same day (16 October), convening 18 representatives from Hong Kong and other Asian countries/regions to share their insights.

The organizers express their gratitude for the funding from the Cultural and Creative Industries Development Agency (CCIDA), and for the strong support from various partners, supporting organizations, and speakers. The highlights of all events will be uploaded to https://contest2025.bestasiainnovation.hk/ for review by all sectors.

About the Hong Kong Wireless Technology Industry Association

The Wireless Technology Industry Association (WTIA), established in 2001, is a not-for profit, politically-neutral trade association dedicated to the wireless and mobile industry. The WTIA acts as a platform, an aggregator, and a community for industry professionals to learn and drive emerging wireless and mobile technologies, governance, and standards. It facilitates networking between like-minded professionals, boost interoperability between networks and devices, and strives to help all organisations apply these technologies to existing or new businesses. The WTIA also represents and is supported by digital industries pertaining to mobile such as digital entertainment, digital marketing & media, and start-up sectors. To know more about the WTIA, please visit http://www.hkwtia.org. 

About Asia Smart Innovation Awards (ASIA)

The Hong Kong Wireless Technology Industry Association (WTIA), proudly presents The Asia Smart Innovation Awards 2025 (formerly known as the Asia Smart App Awards). This year marks a significant transformation, expanding its scope to celebrate not only smart apps but also innovative smart solutions across industries such as media, digital art, and entertainment. The awards unite 17 regional co-organisers from across Asia, including Bangladesh, Cambodia, India, Indonesia, Israel, Japan, Korea, the Mainland, Malaysia, Myanmar, Pakistan (NEW), the Philippines, Singapore, Sri Lanka, Taiwan, China, Thailand, and Vietnam. This collaborative effort highlights Hong Kong’s pivotal role as a key connector in the region’s tech ecosystem, fostering technological advancement and showcasing transformative innovations. For more details about the ASIA, please visit: https://contest2025.bestasiainnovation.hk/

About the Cultural and Creative Industries Development Agency

The Cultural and Creative Industries Development Agency (CCIDA) established in June 2024, formerly known as Create Hong Kong (CreateHK), is a dedicated office set up by the Government of the Hong Kong Special Administrative Region under the Culture, Sports and Tourism Bureau to provide one-stop services and support to the cultural and creative industries with a mission to foster a conducive environment in Hong Kong to facilitate the development of arts, culture and creative sectors as industries. Its strategic foci are nurturing talent and facilitating start-ups, exploring markets, promoting cross-sectoral and cross-genre collaboration, promoting the development of arts, culture and creative sectors as industries under the industry-oriented principle, and promoting Hong Kong as Asia’s creative capital and fostering a creative atmosphere in the community to implement Hong Kong’s positioning as the East-meets-West centre for international cultural exchange under the National 14th Five-Year Plan. CCIDA’s website: www.ccidahk.gov.hk.

This press release is presented by Market Hubs Holdings Limited on behalf of the Hong Kong Wireless Technology Industry Association.

Media Enquiry:

Market Hubs Holdings Limited

Lierence Li 

Debbie So

+852 3998-4900

+852 3998-4900

lierence@markethubsgroup.com

debbie@markethubsgroup.com

 

Yunji Technology Debuts on HKEX, Partners with Luxshare Precision to Accelerate Global Expansion

By
Advertorial Desk
-

HONG KONG, Oct. 18, 2025 /PRNewswire/ — Beijing Yunji Technology Co., Ltd. (the “Company“; Stock code: 2670) today announced that shares of the Company have started to be traded on the Main Board of The Stock Exchange of Hong Kong Limited under the stock code “2670”.

Shares of the Company were actively traded on the first day of listing, with an intraday high of HK$142.80 per Share and closed at HK$120.50 per Share, representing an increase of approximately 26.05% from the offer price of HK$95.60. Total trading volume was approximately 3.23 million shares today, representing an aggregate turnover of approximately HK$484 million.

Commenting on the positive reaction of the market, the Company said, “in the future, we will continuous enhancing commercialization capabilities through exploring broader use cases and creating a vibrant ecosystem; optimizing our products and services to enhance their adaptability across various industry verticals; improving our technological capabilities; and expanding our global presence.”

Yunji Technology is a star robot company in Chinese Mainland, achieving a deployment rate of 99% across the country and becoming a standard for intelligence in the hotel industry. Its globally leading fully autonomous learning system realizes a complete closed loop from perception, cognition, decision-making, execution, to feedback, without any manual intervention throughout the process.

According to the Frost & Sullivan report, in 2024, Yunji Technology Technology will rank first globally in terms of both the scale of online robots in 3D space scenarios and the number of service users: with a single-day peak of 36,000 units, an annual service volume exceeding 500 million times, and a monthly instruction execution volume exceeding 18.6 billion times.

As of now, the company has served over 34000 corporate clients, covering a wide range of settings, including over 34,000 hotels, more than 150 hospitals, and various other scenarios like factories and commercial buildings, demonstrating excellent cross industry service capabilities.

The company announced a strategic partnership with Luxshare Precision(stock code: 002475)to jointly accelerate global business expansion.

The collaboration with Luxshare Precision will enhance Yunji’s capabilities in global supply chain integration, cross-region deployment, and ecosystem development. A representative of Yunji Technology stated, “Through this partnership, we will further optimize our robotic solutions and expand into broader international markets.”

The Company will leverage its listing and the new partnership to drive technological innovation and global presence, creating sustainable value for shareholders and society.

Looking forward, taking the listing as an opportunity, the Company will leverage on the global capital to further promote its business development, strive for outstanding performance, and give back to the shareholders, the society and the public.

About Beijing Yunji Technology Co., Ltd.

Beijing Yunji Technology Co., Ltd. holds a leading position in the hospitality robotic-based AI agents market in China. The Company primarily offers robots and functional kits, complemented by services under AI digitalization system. From robots that interact with the physical world to AI digitalization system that streamline decision-making, the Company delivers adaptive and scalable products and services to its customers. An AI agent is an artificial intelligence that possesses autonomous perception, memory, reasoning analysis, decision-making and action execution capabilities, which can directly provide end-to-end and continuous iterative solutions tailored to specific tasks. During the Track Record Period, the Company primarily focused on the development of hospitality robotic-based AI agent.

Japan Officially Opens Its Market to Colombian Chicken

By
Advertorial Desk
-

Colombia achieves its first export of chicken meat to Japan, marking a historic milestone in the opening of Asian markets for the country’s agribusiness sector.

BOGOTÁ, Colombia, Oct. 18, 2025 /PRNewswire/ — Thanks to the joint efforts of ProColombia and the private sector, Colombia has completed its first export of chicken meat to Japan—one of the world’s most demanding markets in terms of sanitary and quality standards. This achievement represents a decisive step in diversifying Colombia’s export portfolio toward Asia and positions the Colombian poultry industry as a reliable supplier on the global stage.

Courtesy of ProColombia.
Courtesy of ProColombia.

This milestone is the result of years of technical, sanitary, and diplomatic collaboration, culminating in the first shipment of 12 tons of poultry meat by Cargill Food Latin America (Pollos El Bucanero S.A.)

According to Carmen Caballero, President of ProColombia, “this success is strengthened by the bonds of trust and cooperation built during Expo Osaka 2025, where Colombia reinforced its presence and reaffirmed to Japan its commitment to offering a modern, safe, and competitive agribusiness industry.”

The process to gain Japan’s sanitary approval for Colombian chicken began ten years ago, when Japan issued the phytosanitary protocol allowing the product’s potential entry into its market. On July 28, 2023, Japan’s Ministry of Agriculture, Forestry and Fisheries (MAFF) lifted initial restrictions, and on March 13, 2025, the country officially removed all remaining barriers to imports.

To achieve this breakthrough, ProColombia‘s office in Tokyo coordinated closely with the Embassy of Colombia in Japan, Colombian sanitary authorities, and the National Federation of Poultry Farmers of Colombia (Fenavi), along with MAFF and Japan’s Animal Quarantine Service. The agency also facilitated opportunities with Colombian companies such as Cargill and Pollos El Dorado since 2020, and supported Fenavi’s participation in Foodex Japan 2024, under the national brand “Colombia, the Country of Beauty.”

Colombian Poultry Sector Advances in Egg Exports

In addition to chicken meat, ProColombia has been supporting the internationalization of table eggs and processed products, fostering business connections and market intelligence tools that have already enabled the export of over 170 containers.

This progress is part of Colombia’s national strategy to diversify markets and enhance the sophistication of its agribusiness supply, with Japan identified as a priority destination for strengthening Colombia’s reputation for quality, sustainability, and reliability.

Photo – https://laotiantimes.com/wp-content/uploads/2025/10/procolombia.jpg

1...1,9341,9351,936...6,308Page 1,935 of 6,308